James Smoliga, DVM, PhD
Chair of the Scientific Advisory Board
Department of Physical Therapy, Department of Basic Pharmaceutical Sciences, High Point University, High Point, North Carolina
Dr. Smoliga is the Associate Director of the High Point University Human Biomechanics and Physiology Laboratory and is also a Fellow of the American College of Sports Medicine (FACSM). Dr. Smoliga is an active scholar with over 50 peer-review publications the areas of human physiology, translational medicine (with a focus on resveratrol), and sports medicine, including prestigious journals such as Nature, British Medical Journal (BMJ), and JAMA Neurology. Dr. Smoliga also serves as a reviewer for over 50 scientific and medical journals. He is a recognized expert in resveratrol, with publications addressing human clinical trial design, cardiovascular biomarkers, treatment of diabetes, and dose optimization of resveratrol. Dr. Smoliga’s research interest extends into research design and statistical methodology, as well as addressing inaccuracies and misinterpretation of scientific research. Additionally, Dr. Smoliga teaches the cardioavascular and pulmonary physiology, and pathophysiology content for Doctor of Physical Therapy (DPT) students at High Point University. Dr Smolgia earned a Doctor of Veterinary Medicine degree from Cornell University in 2003 and a PhD in Sports Medicine and Nutrition from the University of Pittsburgh in 2007.
Joseph Baur PhD
Assistant Professor, Department of Physiology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania
Dr. Baur is an Assistant Professor of Physiology in the Institute for Diabetes, Obesity, and Metabolism and the Department of Physiology at the University of Pennsylvania. He is among the most respected and most cited Resveratrol researchers. Early in his career he developed a strong interest in the regulation of aging and metabolism by sirtuins, a conserved class of enzymes that influence metabolic health in mammals and lifespan in lower organisms. During his time as a postdoctorial fellow at Harvard Medical School he worked with Dr. David Sinclair, who first reported that the effects of resveratrol include activation of the sirtuin SIRT1. Dr. Baur extended these findings to establish that resveratrol improves insulin sensitivity and decreases mortality in obese mice.
Dr. Baur earned his PhD from the University of Texas Southwestern Medical Center in Dallas, Texas, where he studied mechanisms that limit the lifespan of cultured human cells under doctors Jerry Shay and Woody Wright.
Marina K. Holz, Ph.D.
Professor and the Doris and Ira Kukin Chair in Biology at Yeshiva University, New York, New York and the Albert Einstein Cancer Center, Albert Einstein College of Medicine, Bronx, New York
Dr. Holz’ research is focused on the interaction between the mechanistic target of rapamycin (mTOR) pathway & estrogen receptor signaling in various diseases including lymphangioleiomyomatosis and breast cancer. Dr. Holz has an interest in combination therapies in clinic, including the coadministration of resveratrol with rapamycin (sirolimus).
Dr. Holz received her Bachelors of Science degree from McGill University in Montreal, Canada. She completed her Ph.D. in Cell Biology at Harvard Medical School.
William D. “Scott” Killgore PhD
Professor and Director of the Social, Cognitive, and Affective Neuroscience (SCAN) Lab, Department of Psychiatry, University of Arizona, Tuscon, Arizona.
Dr. William D “Scott” Killgore’s work combines neurocognitive assessment with state-of-the-art neuroimaging methods, including functional and structural magnetic resonance imaging (MRI), to study the role of emotion in complex cognitive processes, such as moral judgment, decision-making and risk-taking. He also is interested in how these brain-behavior systems may be affected by environmental and lifestyle factors, such as insufficient sleep, nutrition, light exposure, physical activity and stimulants, such as caffeine.
As Principal investigator, Dr. Killgore currently has over $15.5 million in active grant funding from the Department of Defense to study methods for accelerating recovery from mild traumatic brain injury and post-traumatic stress disorder. Presently, Dr. Killgore is principal investigator on multiple projects, including three aimed at improving sleep-wake patterns among individuals with mild traumatic brain injuries and/or post-traumatic stress disorder, as well as a study focused on modeling the recovery patterns at various stages of recovery following concussion. He recently completed a DARPA funded study to identify the neurocircuitry that underlies the ability to sustain cognitive resilience during periods of sleep deprivation.
Dr. Killgore also has over 15 years of military service, including 5 years on active duty as a Medical Service Corps officer and Research Psychologist in the United States Army during the Global War on Terror. While stationed at the Walter Reed Army Institute of Research in Washington, DC, Dr. Killgore served as Chief of the Neurocognitive Performance Branch and Special Volunteer with the National Institute on Deafness and Other Communication Disorders within the National Institutes of Health. Dr. Killgore remains active as a Research Psychologist in the U.S. Army Reserve, currently holding the rank of Lieutenant Colonel.
From 2000-2010, Dr. Killgore was an Instructor in Psychology at Harvard Medical School in Boston, MA, with a 5-year leave of absence during his active military service. Dr. Killgore currently the Director of the Social, Cognitive, and Affective Neuroscience (SCAN) Lab in the Department of Psychiatry at the University of Arizona, & continues to hold a part-time appointment at the rank of Associate Professor at Harvard Medical School.
Raymond Scott Turner MD, PhD
Professor, Director of the Memory Disorders Program, Department of Neurology, Georgetown University, Washington, District Of Columbia
Raymond Scott Turner, MD, PhD, is Professor of Neurology and Director of the Memory Disorders Program at Georgetown University Medical Center. His research focuses on early interventions for Alzheimer’s disease, and his Phase II Clinical Trial with Resveratrol in Alzheimer’s (published in Neurology, 2015) was featured in the Wall Street Journal and Time Magazine. He has received numerous prestigious awards, including a fellowship from the Howard Hughes Medical Institute and a Beeson Scholar award.
Dr. Turner earned his medical degree and a PhD in pharmacology from Emory University, Atlanta, and completed his medical internship, residency and fellowship at the University of Pennsylvania, Philadelphia. He was elected a Fellow with the American Neurological Association in 2006. He has published more than 100 papers, reviews, and book chapters. For more information regarding Dr Turner’s work in Neurology, please see memory.georgetown.edu.